Healthcare / BiotechnologyNasdaqGS
$12.29
-0.04 (-0.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-103.2M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$196M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-50.6%
↓Gross Margin
49.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-787.5%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.1M · net income $-124.0M · FCF $-103.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $13.1M | $13.1M | $10.1M | $7.8M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-124.0M | $-124.0M | $-130.0M | $-116.7M | $-110.2M | $-92.3M | $-50.5M | $-28.6M | $-26.1M | $-21.1M | $-38.8M | $-48.1M | $-27.6M | $-10.9M | $-9.4M | $-3.5M | $-2.0M | $-221000.00 | $-202000.00 |
| EBITDA | $-122.0M | $-122.0M | $-125.4M | $-114.1M | $-110.8M | $-92.3M | $-50.5M | $-28.8M | $-26.3M | $-21.2M | $-38.8M | $-48.0M | $-27.6M | $-10.9M | — | — | — | — | — |
| EPS | -14.57 | -14.57 | -176.60 | -14720.25 | -65400.00 | -162000.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 49.3% | 49.3% | 23.1% | 39.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -936.1% | -936.1% | -744.5% | -1523.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -946.2% | -946.2% | -1288.3% | -1501.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.06 | 0.09 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 6.99 | 6.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-103.2M | $-103.2M | $-61.0M | $-109.9M | $-146.2M | $-110.9M | $-57.1M | $-26.7M | $-24.0M | $-19.1M | $-37.4M | — | — | — | $-10.2M | $-2.6M | $-1.3M | — | — |
| Returns | |||||||||||||||||||
| ROE | -50.6% | -50.6% | -93.2% | -110.6% | -53.2% | -42.2% | -57.6% | -303.9% | -110.2% | -85.8% | -153.2% | -119.4% | -76.5% | -167.1% | -985.4% | 141.4% | 1122.3% | 41.2% | 37.1% |
| Valuation | |||||||||||||||||||
| P/B | 0.43 | 0.43 | 0.16 | 0.09 | 0.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | 29.8% | 29.8% | 29.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 91.7% | 91.7% | 98.8% | 77.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-69.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-176.60 → -14.57
Residual
-69.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.